## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.3% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: declining volume (46% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($326.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cencora Stock: Quiet Rally, Firm Fundamentals and a Market Looking for the Next Catalyst**
- Source: AD HOC NEWS | 20251230T150242 | Bullish | Relevance: 100%
- Cencora (NYSE: COR) has seen a quiet but steady rally, outperforming other healthcare distributors due to firm fundamentals and positive analyst sentiment. The stock is trading near its 52-week high, with investors recognizing its role as a high-quality compounder in healthcare logistics. Analysts maintain largely positive views, with consensus price targets suggesting continued upside for the company.

**2. Pacer Advisors Inc. Sells 880,384 Shares of Cencora, Inc. $COR**
- Source: MarketBeat | 20251230T105610 | Neutral | Relevance: 100%
- Pacer Advisors Inc. significantly reduced its stake in Cencora (NYSE:COR) by 97.8%, selling 880,384 shares in Q3, but still holds 20,187 shares valued at $6.31 million. Insiders EVP Silvana Battaglia and CEO Robert P. Mauch also sold shares in December, totaling 20,317 shares worth approximately $7.01 million over the last three months, though insiders still own 10.8% of the company. Wall Street analysts maintain a "Moderate Buy" rating with a consensus target price of $373.25, with some firms raising their price targets after Cencora reported strong Q3 earnings and increased its dividend.

**3. Here's Why You Should Retain Glaukos Stock in Your Portfolio Now**
- Source: Finviz | 20251229T160921 | Somewhat-Bullish | Relevance: 63%
- Glaukos Corporation is well-positioned for growth due to the successful launch of its iDose TR product and its robust product pipeline, despite facing stiff competition. The company's shares have significantly outperformed the industry this year, driven by strong adoption of iDose TR and the recent FDA approval of Epioxa, which is set to boost its corneal health franchise. While reimbursement complexities and a temporary revenue disruption during the Epioxa transition pose challenges, Glaukos' diversified global growth, strong financial profile, and ongoing innovation support its positive outlook.

**4. The Truth About Cardinal Health Inc.: Quiet Stock, Loud Moves â€“ Are You Sleeping On This Play?**
- Source: AD HOC NEWS | 20251231T181342 | Somewhat-Bullish | Relevance: 62%
- Cardinal Health Inc. recently showed significant market activity, prompting a closer look at whether this healthcare stock is a valuable investment or just a quiet performer. The article explores Cardinal Health's role in the healthcare supply chain, its recent financial performance, and its position against competitors like McKesson and AmerisourceBergen. It aims to help investors decide if this "quiet operator" is a "cop" for long-term, defensive portfolios or a "drop" for those seeking short-term gains.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.5B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.3 |
| Current P/E | 19.3 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.6% to -0.3% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 41. Volume at 46% of 20MA suggests lack of conviction. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.30% (CS: 43) | Neutral |
| RSI_14 | 40.8 | Neutral |
| MACD Histogram | -0.45 | Bearish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 0.970x | Below |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $337.79
- **Stop Loss:** $326.77 (3.3% risk)
- **Target:** $348.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $43,912.70
- **Portfolio %:** 43.91%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*